A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy,
safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the
Alzheimer’s type.

Brief description of study

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.